Noxopharm Ltd. · ASX:NOX
Noxopharm — Shareholder Meeting (November 2023)
37 slides from Noxopharm's shareholder meeting presentation, Nov 16, 2023
Slide 1: Noxopharm 2023 AGM Corporate Presentation
Noxopharm 2023 AGM Corporate Presentation Sydney, 16 November 2023: Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to release its 2023 AGM Corporate Presentation. Highlights: • Strategic transformation • Two proprietary technology platforms with multiple assets • Encouraging precl
Slide 2: Forward-looking statements
This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “wo
Slide 3: Noxopharm Limited – AGM 2023
NOXOPHARM LIMITED Delivering Science. Transforming Lives. AGM 2023 NOXOPHARM (ASX:NOX) DELIVERING SCIENCE. TRANSFORMING LIVES.
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be
Slide 5: Noxopharm – Dr Gisela Mautner, CEO & MD
Noxopharm Dr Gisela Mautner, CEO & MD AGM 16 November 2023
Slide 6: Transforming Noxopharm
Transforming Noxopharm • Noxopharm – transforming to build shareholder value: • New strategic direction • Two proprietary technology platforms • Multiple high-potential assets • Encouraging results • World-class partners • Robust IP portfolio • Experienced management team • Significant market opport
Slide 7: Past 12 Months – Review
Past 12 Months – Review Corporate • Strategic decision to focus on two promising platforms • Resources directed towards principal objectives • Careful management of cash ChromaTM SofraTM • Positive pancreatic cancer drug data in preclinical • Positive results from SOF-VACTM studies models • SOF-VAC
Slide 8: IONIC Trial Update
IONIC Trial Update • IONIC is a pilot Phase 1 trial exploring the safety and efficacy signals of Veyonda® combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo® (nivolumab) for the treatment of a range of solid tumour types. • Professor De Souza and investigators are responsible for the
Slide 9: Financial Summary (ASX:NOX)
Financial Summary (ASX:NOX) Capital Structure* Cash Position** Share price $0.135 Current Cash Holdings $7.9M Shares on issue 292M R&D rebate received for 2022/23 $6.1M Market Capitalisation $39.5M Net capital raised1 $63.8M Govt grants/rebates received2 $29.6M * As at 14 Nov 2023 ** As at 16 Nov 20
Slide 10: The Noxopharm Business Model
The Noxopharm Business Model Proprietary and in-licensed drugs are advanced through Out-licensing drug development, with a Upfront payment Milestones view to out-licensing them at Royalties key value inflection points. Clinical Pre-Clinical Out-licensing Upfront payment Milestones Own & Royalties In
Slide 11: Two Separate Preclinical Development Programs
Two Separate Preclinical Development Programs Noxopharm (ASX:NOX) - November 2023 9
Slide 12: Preclinical Platforms – Key Characteristics
Preclinical Platforms – Key Characteristics • The Chroma and Sofra technology platforms share key attributes that are important value drivers: • Uniqueness • New and proprietary drug candidates from both platforms • Protected by robust Intellectual Property strategy • World-class partnerships • Huds
Slide 13: Noxopharm Chroma
Noxopharm Chroma TM
Slide 14: Chroma Tech Platform
Cancer Inflammation CHROMA™ TECH PLATFORM Pancreatic Cancer ; TBK1/ Inflammation Brain Cancer — VS Other Cancers NOXOPHARM
Slide 15: Pancreatic Cancer Dual-Cell Therapy
Pancreatic Cancer Dual-Cell Therapy • Preclinical research in unique pancreatic cancer UNSW model. • CRO-67 tested in patient-derived explants. • CRO-67 attacks both pancreatic tumour cells and barrier cells surrounding the tumour. • Reducing the barrier exposes tumour to immune cells and to further
Slide 16: Latest Data – Significantly Reduced Tumour Volume and Slower Growth
Latest Data – Significantly Reduced Tumour Volume and Slower Growth • In vivo research results presented at the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer in September 2023. • Human pancreatic cancer tumour cells implanted under the skin into mice. • Treat
Slide 17: Orphan Drug Designation
Orphan Drug Designation • Granted by US Food and Drug Administration in October 2023. • ODDs given for drugs designed to prevent, diagnose or treat rare diseases or conditions. • Designation comes with various benefits that include: • Tax credits for qualified clinical trials • Exemption from user f
Slide 18: CRO-67 – Next Steps
CRO-67 – Next Steps • High priority project • Further in vivo studies currently underway • Mechanism of action • Dosing • Formulation Noxopharm (ASX:NOX) - November 2023 16
Slide 19: Noxopharm Sofra
Noxopharm SofraTM
Slide 20: Sofra
Sofra • Noxopharm has in-licensed a technology from Hudson Institute of Medical Research to create the Sofra technology platform, which is housed in Noxopharm’s subsidiary Pharmorage. • This technology platform is based upon short nucleic acid sequences, the building blocks of DNA or RNA, known as o
Slide 21: Stimulate Inflammatory Response
Stimulate Inflammatory Response Infectious Inflammatory Diseases Cancer Cardiovascular Diseases ) _ J® . NOXOPHARM : SOFRA™ TECH PLATFORM 4 a, mRNA \ J Oligonucleotides targeting inflammatory sensors Weeds Other therapeutics Neurodegenerative Diseases Parkinson's Alzheimer's Huntington's Multiple Sc
Slide 22: SOF-SKN – Overview
SOF-SKNTM – Overview • Noxopharm is developing an oligonucleotide-based skin medication. • Previously known as SOF-XX, now termed SOF-SKN. • The oligonucleotides act to reduce inflammation at its source. • Potential application in autoimmune diseases like lupus and psoriasis. • When applied topicall
Slide 23: SOF-SKN Reduces Skin Inflammation in Mouse Model
SOF-SKN Reduces Skin Inflammation in Mouse Model Noxopharm (ASX:NOX) - November 2023
Slide 24: SOF-SKN – Next Steps
SOF-SKN – Next Steps • Science-driven strategy – accelerate SOF-SKN project as rapidly as possible. • Market opportunity – potential novel treatment for inflammatory skin diseases like lupus and / or psoriasis. • Global immunology market is projected to grow from USD 92 billion in 2021 to USD 158 bi
Slide 25: Stimulate Inflammatory Response
Stimulate Inflammatory Response Infectious Inflammatory Diseases SOFRA™ TECH PLATFORM Oligonucleotides targeting inflammatory sensors Cancer Neurodegenerative Diseases + Parkinson's + Alzheimer's + Huntington's + Multiple Sclerosis Cardiovascular Diseases — -» + Hypertension: NOXOPHARM : purges Pulm
Slide 26: Katalin Kariko and Drew Weissman – Nobel Prize 2023
Katalin Kariko ‘The Mobel Prize in Physiology or Medicine 2023 Nobelpcisat | Fysiotogs eer Medicin 2023 Drew Weissman
Slide 27: Nobel press release quote on mRNA and the immune system
…fundamentally changed our understanding on how mRNA interacts with our immune system… Press release: The Nobel Prize in Physiology or Medicine 2023 - NobelPrize.org
Slide 28: Nobel press release quote on inflammatory response
… The results were striking: The inflammatory response was almost abolished when base modifications were included in the mRNA. Press release: The Nobel Prize in Physiology or Medicine 2023 - NobelPrize.org
Slide 29: Press release: The Nobel Prize in Physiology or Medicine 2023
Press release: The Nobel Prize in Physiology or Medicine 2023 - NobelPrize.org
Slide 30: SOF-VAC – Mechanism of Action
SOF-VACTM – Mechanism of Action Noxopharm (ASX:NOX) - November 2023
Slide 31: SOF-VAC – Benefits
SOF-VAC – Benefits The ability of SOF-VAC to reduce the inflammatory side effects of mRNA vaccines or drugs has several potential benefits, such as: • Enabling mRNA vaccines to be given with higher doses – creating longer- lasting protection and a decrease in the frequency of booster shots required.
Slide 32: SOF-VAC – Recent Data
SOF-VAC – Recent Data • In an animal study, inflammation was reduced by around 50% when comparing the inflammation induced by mRNA alone to mRNA plus SOF-VAC. • This is an important finding, as many side effects of mRNA vaccines are due to inflammation. • Since mRNA expression is directly correlated
Slide 33: SOF-VAC – Delivery Mechanism
SOF-VAC – Delivery Mechanism SOF-VAC can be successfully co-packaged with mRNA inside an FDA-approved delivery system (LNP) without impacting the integrity of the LNPs. LNP = lipid nanoparticle Noxopharm (ASX:NOX) - November 2023 31
Slide 34: SOF-VAC – Overview
SOF-VACTM – Overview • SOF-VAC based on short nucleic acid sequences known as oligonucleotides. • Ultra short oligonucleotides comprising three bases (3-mers). • 3-mers act on Toll-like receptor 7 (TLR7) – a specific sensor to modulate inflammation at its source. • SOF-VAC suitable as adjunct for: •
Slide 35: SOF-VAC – Next Steps
SOF-VAC – Next Steps • COVID-19 vaccines are projected to make up most of the mRNA market until 2025. • Other prophylactic vaccines, therapeutic vaccines, and therapeutics will then become larger shares. • The mRNA market is forecast to be USD 137 billion by 2032. • SOF-VAC gives potential customers
Slide 36: Summary
Summary Program Discovery Screening Preclinical Collaborators CRO-67 Pancreatic Cancer UNSW Sydney Chroma Hudson Institute of SOF-VAC Adjuvant for mRNA vaccines Medical Research Hudson Institute of SOF-SKN Autoimmune skin disease Medical Research Sofra Noxopharm (ASX:NOX) - November 2023 34
Slide 37: Noxopharm Questions
Noxopharm Questions